NCT01953523已完成不适用
Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.
Elliot Lander2 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2013年9月2日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 3,000
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study monitors the results of subjective and objective findings as it applies to the non-blinded deployment of autologous SVF for various inflammatory and/or degenerative conditions including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF deployments include intra-venous, intra-articular, and soft tissue injections.
详细描述
SVF Stromal Vascular Fraction is obtained by lipoharvesting, procurement, and lipo-transfer as a same day operative procedure
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patient must be age 16 or older
- •Patient must have a degenerative disease or inflammatory disease that meets criteria for treatment under the IRB which includes: Arthritis, Auto-immune disease,COPD, Cardiomyopathy, Peyronies Disease,Interstitial Cystitis, Erectile Dysfunction, and Neurodegenerative disease such as Parkinsons, ALS, Neuropathy.
- •Patient must be healthy enough to tolerate a local anesthetic
排除标准
- •Patient must not have active cancer
- •Patient must not have active infection
研究组 & 干预措施
Deployment of stromal vascular fraction
Experimental
Administration of autologous adipose derived SVF
干预措施: Administration of autologous adipose derived SVF (Procedure)
结局指标
主要结局
Number of participants with adverse events
时间窗: Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.
Outcome measures will include the number of participants with adverse events related to either SVF deployment or the lipo-harvesting procedure.
次要结局
- Changes in Koos Physical Function Shortform(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the Oswestry Disability Index(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the Neck Disability Index(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in Hoos Physical Function Shortform(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the Aqol-4(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the O'leary-Sant IC Questionnaire(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- EHGS Grading Score measuring change in hardness score(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the DASH questionnaire(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the Visual Analog Pain Score(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in PUF Symptom Scale(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
- Changes in the IIEF Questionnaire(Outcome measures will be evaluated at baseline, 3,6,9,12,15,18,21,24,27,30,33,36 months. Outcomes tests will be given yearly after 36 months for an average time frame of 5 years and estimated time frame maximum of 10 years.)
研究者
Elliot Lander
Medical Director
Cell Surgical Network Inc.
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Therapeutic Drug Monitoring for Individualized Clozapine TherapySchizophreniaNCT03523741Seoul National University Hospital100
已完成
不适用
Assessment of treatment efficacy and adverse effects of Microrelin in patient with prostate cancer.IRCT201109067457N4Pooyesh darou company40
撤回
不适用
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) TreatmentThrombosis, Deep VeinPulmonary EmbolismNCT03812835Pfizer
已完成
1 期
An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult VolunteersHealthy SubjectNCT05832697Daewoong Pharmaceutical Co. LTD.44
招募中
不适用
The evaluation of adverse events and theraputic effects using divided CDDP for advanced urothelial carcinoma patients with Chronic Kidney Disease.rothelial CarcinomaJPRN-UMIN000009202agoya Univerity, Depatment of Urology20